Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashExchange Rate EffectFree Cash FlowNet Cash FlowNet IncomeShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Spyre Therapeutics (SYRE) Shares Issued: 2017-2025

Historic Shares Issued for Spyre Therapeutics (SYRE) over the last 8 years, with Sep 2025 value amounting to $491,000.

  • Spyre Therapeutics' Shares Issued rose 323.18% to $491,000 in Q3 2025 from the same period last year, while for Sep 2025 it was -$159.8 million, marking a year-over-year decrease of 194.47%. This contributed to the annual value of $7.5 million for FY2024, which is 1754.57% up from last year.
  • According to the latest figures from Q3 2025, Spyre Therapeutics' Shares Issued is $491,000, which was down 32.83% from $731,000 recorded in Q2 2025.
  • In the past 5 years, Spyre Therapeutics' Shares Issued registered a high of $169.2 million during Q1 2024, and its lowest value of -$161.3 million during Q4 2024.
  • For the 3-year period, Spyre Therapeutics' Shares Issued averaged around $947,300, with its median value being $193,500 (2023).
  • Within the past 5 years, the most significant YoY rise in Spyre Therapeutics' Shares Issued was 939,927.78% (2024), while the steepest drop was 57,312.41% (2024).
  • Over the past 5 years, Spyre Therapeutics' Shares Issued (Quarterly) stood at $249,000 in 2021, then slumped by 96.96% to $38,000 in 2022, then surged by 176.32% to $282,000 in 2023, then slumped by 57,312.41% to -$161.3 million in 2024, then spiked by 323.18% to $491,000 in 2025.
  • Its Shares Issued was $491,000 in Q3 2025, compared to $731,000 in Q2 2025 and $335,000 in Q1 2025.